The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk
Open accessAbstract
Tuberculosis remains second only to HIV/AIDS as the leading cause of mortality worldwide due to a single infectious agent. Despite chemotherapy, the global tuberculosis epidemic has intensified because of HIV co-infection, the lack of an effective vaccine and the emergence of multi-drug-resistant bacteria. Alternative host-directed strategies could be exploited to improve treatment efficacy and outcome, contain drug-resistant strains and reduce disease severity and mortality. The innate inflammatory response elicited by Mycobacterium tuberculosis (Mtb) represents a logical host target. Here we demonstrate that interleukin-1 (IL-1) confers host resistance through the induction of eicosanoids that limit excessive type I interferon (IFN) production and foster bacterial containment. We further show that, in infected mice and patients, reduced IL-1 responses and/or excessive type I IFN induction are linked to an eicosanoid imbalance associated with disease exacerbation. Host-directed immunotherapy with clinically approved drugs that augment prostaglandin E2 levels in these settings prevented acute mortality of Mtb-infected mice. Thus, IL-1 and type I IFNs represent two major counter-regulatory classes of inflammatory cytokines that control the outcome of Mtb infection and are functionally linked via eicosanoids. Our findings establish proof of concept for host-directed treatment strategies that manipulate the host eicosanoid network and represent feasible alternatives to conventional chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Humason, G. L. (1962) · W.H. Freeman eBooks · doi:10.5962/bhl.title.5890 · Cited by 3,647
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators
Serhan, C. N., Chiang, N., & Van Dyke, T. E. (2008) · Nature Reviews Immunology · doi:10.1038/nri2294 · Cited by 2,932
An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis
Berry, M. P. R., Graham, C. M., McNab, F. W., Xu, Z., Bloch, S. A. A., Oni, T., Wilkinson, K. A., Banchereau, R., Skinner, J., Wilkinson, R. J., et al. (2010) · Nature · doi:10.1038/nature09247 · Cited by 1,898
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
Barry, C. E., Boshoff, H. I., Dartois, V., Dick, T., Ehrt, S., Flynn, J., Schnappinger, D., Wilkinson, R. J., & Young, D. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2236 · Cited by 1,422
The Immune Response in Tuberculosis
O'Garra, A., Redford, P. S., McNab, F. W., Bloom, C. I., Wilkinson, R. J., & Berry, M. P. R. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095939 · Cited by 1,342
Sowter, C. (1980) · Journal of Clinical Pathology · doi:10.1136/jcp.33.2.203-d · Cited by 1,206
Gandhi, N. R., Nunn, P., Dheda, K., Schaaf, H. S., Zignol, M., van Soolingen, D., Jensen, P., & Bayona, J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60410-2 · Cited by 1,018
Lawn, S. D., & Zumla, A. I. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62173-3 · Cited by 751
Manca, C., Tsenova, L., Bergtold, A., Freeman, S., Tovey, M., Musser, J. M., Barry, C. E., Freedman, V. H., & Kaplan, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091096998 · Cited by 595
Host Genotype-Specific Therapies Can Optimize the Inflammatory Response to Mycobacterial Infections
Tobin, D. M., Roca, F. J., Oh, S. F., McFarland, R., Vickery, T. W., Ray, J. P., Ko, D. C., Zou, Y., Bang, N. D., Chau, T. T. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.023 · Cited by 580
Cited by
Type I interferons in infectious disease
McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780
Self-citationPathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
Merad, M., & Martin, J. C. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0331-4 · Cited by 2,472
Eicosanoid storm in infection and inflammation
Dennis, E. A., & Norris, P. C. (2015) · Nature Reviews Immunology · doi:10.1038/nri3859 · Cited by 1,517
Channappanavar, R., Fehr, A. R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D. K., & Perlman, S. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.01.007 · Cited by 1,419
Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.76 · Cited by 1,270
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Zelenay, S., van der Veen, A. G., Böttcher, J. P., Snelgrove, K. J., Rogers, N., Acton, S. E., Chakravarty, P., Girotti, M. R., Marais, R., Quezada, S. A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.015 · Cited by 1,128
Mitochondrial DNA in inflammation and immunity
Riley, J. S., & Tait, S. W. (2020) · EMBO reports · doi:10.15252/embr.201949799 · Cited by 865
Host-directed therapies for bacterial and viral infections
Kaufmann, S. H. E., Dorhoi, A., Hotchkiss, R. S., & Bartenschlager, R. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.162 · Cited by 831
A blood RNA signature for tuberculosis disease risk: a prospective cohort study
Zak, D. E., Penn-Nicholson, A., Scriba, T. J., Thompson, E., Suliman, S., Amon, L. M., Mahomed, H., Erasmus, M., Whatney, W., Hussey, G. D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01316-1 · Cited by 780
Immune evasion and provocation by Mycobacterium tuberculosis
Chandra, P., Grigsby, S. J., & Philips, J. A. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00763-4 · Cited by 614
T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4 + T cells
Arbore, G., West, E. E., Spolski, R., Robertson, A. A. B., Klos, A., Rheinheimer, C., Dutow, P., Woodruff, T. M., Yu, Z. X., O’Neill, L. A., et al. (2016) · Science · doi:10.1126/science.aad1210 · Cited by 513
Self-citationCadena, A. M., Fortune, S. M., & Flynn, J. L. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.69 · Cited by 484
Host Evasion and Exploitation Schemes of Mycobacterium tuberculosis
Cambier, C. J., Falkow, S., & Ramakrishnan, L. (2014) · Cell · doi:10.1016/j.cell.2014.11.024 · Cited by 426
Cytokines and Chemokines in Mycobacterium tuberculosis Infection
Domingo-Gonzalez, R., Prince, O., Cooper, A., & Khader, S. A. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.tbtb2-0018-2016 · Cited by 404
Zumla, A., Rao, M., Wallis, R. S., Kaufmann, S. H. E., Rustomjee, R., Mwaba, P., Vilaplana, C., Yeboah-Manu, D., Chakaya, J., Ippolito, G., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00078-5 · Cited by 402
Wassermann, R., Gulen, M. F., Sala, C., Perin, S. G., Lou, Y., Rybniker, J., Schmid-Burgk, J. L., Schmidt, T., Hornung, V., Cole, S. T., et al. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.05.003 · Cited by 401
Tiberi, S., du Plessis, N., Walzl, G., Vjecha, M. J., Rao, M., Ntoumi, F., Mfinanga, S., Kapata, N., Mwaba, P., McHugh, T. D., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30110-5 · Cited by 396
Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection
Bell, L. C. K., & Noursadeghi, M. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.128 · Cited by 389
25-Hydroxycholesterols in innate and adaptive immunity
Cyster, J. G., Dang, E. V., Reboldi, A., & Yi, T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3755 · Cited by 388
Identification of resolvin D2 receptor mediating resolution of infections and organ protection
Chiang, N., Dalli, J., Colas, R. A., & Serhan, C. N. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150225 · Cited by 383
T cells and adaptive immunity to Mycobacterium tuberculosis in humans
Jasenosky, L. D., Scriba, T. J., Hanekom, W. A., & Goldfeld, A. E. (2015) · Immunological Reviews · doi:10.1111/imr.12274 · Cited by 362
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses
Lenaerts, A., Barry, C. E., & Dartois, V. (2015) · Immunological Reviews · doi:10.1111/imr.12252 · Cited by 362
Sakai, S., Kauffman, K. D., Sallin, M. A., Sharpe, A. H., Young, H. A., Ganusov, V. V., & Barber, D. L. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005667 · Cited by 347
Self-citationThe Roles of Type I Interferon in Bacterial Infection
Boxx, G. M., & Cheng, G. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.05.016 · Cited by 335
Moorlag, S. J. C. F. M., Khan, N., Novakovic, B., Kaufmann, E., Jansen, T., van Crevel, R., Divangahi, M., & Netea, M. G. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107634 · Cited by 335
Interleukin-1β Induces mtDNA Release to Activate Innate Immune Signaling via cGAS-STING
Aarreberg, L. D., Esser-Nobis, K., Driscoll, C., Shuvarikov, A., Roby, J. A., & Gale, M. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.02.038 · Cited by 328
Inflammasome activation at the crux of severe COVID-19
Vora, S. M., Lieberman, J., & Wu, H. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00588-x · Cited by 325
Alveolar Macrophages in the Resolution of Inflammation, Tissue Repair, and Tolerance to Infection
Allard, B., Panariti, A., & Martin, J. G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01777 · Cited by 324
Gleeson, L. E., Sheedy, F. J., Palsson-McDermott, E. M., Triglia, D., O’Leary, S. M., O’Sullivan, M. P., O’Neill, L. A. J., & Keane, J. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501612 · Cited by 319
Immunology of Mycobacterium tuberculosis Infections
Sia, J. K., & Rengarajan, J. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0022-2018 · Cited by 312
Inflammatory signaling in human tuberculosis granulomas is spatially organized
Marakalala, M. J., Raju, R. M., Sharma, K., Zhang, Y. J., Eugenin, E. A., Prideaux, B., Daudelin, I. B., Chen, P.-Y., Booty, M. G., Kim, J. H., et al. (2016) · Nature Medicine · doi:10.1038/nm.4073 · Cited by 308
Self-citationKhan, N., Downey, J., Sanz, J., Kaufmann, E., Blankenhaus, B., Pacis, A., Pernet, E., Ahmed, E., Cardoso, S., Nijnik, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.062 · Cited by 292
Advancing host-directed therapy for tuberculosis
Wallis, R. S., & Hafner, R. (2015) · Nature Reviews Immunology · doi:10.1038/nri3813 · Cited by 291
Nitric oxide prevents a pathogen-permissive granulocytic inflammation during tuberculosis
Mishra, B. B., Lovewell, R. R., Olive, A. J., Zhang, G., Wang, W., Eugenin, E., Smith, C. M., Phuah, J. Y., Long, J. E., Dubuke, M. L., et al. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.72 · Cited by 284
Self-citationProstaglandin‐cytokine crosstalk in chronic inflammation
Yao, C., & Narumiya, S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14530 · Cited by 283
Type I interferons in tuberculosis: Foe and occasionally friend
Moreira-Teixeira, L., Mayer-Barber, K., Sher, A., & O’Garra, A. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180325 · Cited by 282
Self-citationGideon, H. P., Hughes, T. K., Tzouanas, C. N., Wadsworth, M. H., Tu, A. A., Gierahn, T. M., Peters, J. M., Hopkins, F. F., Wei, J.-R., Kummerlowe, C., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.004 · Cited by 278
Gasdermin D Restrains Type I Interferon Response to Cytosolic DNA by Disrupting Ionic Homeostasis
Banerjee, I., Behl, B., Mendonca, M., Shrivastava, G., Russo, A. J., Menoret, A., Ghosh, A., Vella, A. T., Vanaja, S. K., Sarkar, S. N., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.07.006 · Cited by 261
Host-directed immunotherapy of viral and bacterial infections: past, present and future
Wallis, R. S., O’Garra, A., Sher, A., & Wack, A. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00734-z · Cited by 255
Self-citationDoes tuberculosis threaten our ageing populations?
Byng-Maddick, R., & Noursadeghi, M. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1451-0 · Cited by 149
Moreira-Teixeira, L., Tabone, O., Graham, C. M., Singhania, A., Stavropoulos, E., Redford, P. S., Chakravarty, P., Priestnall, S. L., Suarez-Bonnet, A., Herbert, E., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0610-z · Cited by 127
Self-citationPatrick, K. L., Bell, S. L., Weindel, C. G., & Watson, R. O. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00138 · Cited by 110
Barczak, A. K., Avraham, R., Singh, S., Luo, S. S., Zhang, W. R., Bray, M.-A., Hinman, A. E., Thompson, M., Nietupski, R. M., Golas, A., et al. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006363 · Cited by 120
Shim, D., Kim, H., & Shin, S. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00910 · Cited by 113
Release of mycobacterial antigens
Majlessi, L., Prados‐Rosales, R., Casadevall, A., & Brosch, R. (2015) · Immunological Reviews · doi:10.1111/imr.12251 · Cited by 93
Interfering with immunity: detrimental role of type I IFNs during infection
Stifter, S. A., & Feng, C. G. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402794 · Cited by 78
Gander-Bui, H. T. T., Schläfli, J., Baumgartner, J., Walthert, S., Genitsch, V., van Geest, G., Galván, J. A., Cardozo, C., Graham Martinez, C., Grans, M., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.023 · Cited by 47
Metadata
- Authors
- Mayer-Barber, K. D., Andrade, B. B., Oland, S. D., Amaral, E. P., Barber, D. L., Gonzales, J., Derrick, S. C., Shi, R., Kumar, N. P., Wei, W., Yuan, X., Zhang, G., Cai, Y., Babu, S., Catalfamo, M., Salazar, A. M., Via, L. E., Barry III, C. E., & Sher, A.
- Venue
- Nature
- Published
- 2014-06-25
- Volume
- 511
- Issue
- 7507
- Pages
- 99-103
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1973720948
- Cited by
- 767
- References
- 32
- FWCI
- 51.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.